Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2026)

Ironwood Pharmaceuticals has reported Long-Term Deferred Tax for 6 years, with the latest figure at $84.2 million in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 41.32% year-over-year to $84.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.2 million (down 41.32% YoY) and the FY2025 annual result came in at $103.4 million, down 28.29% from the prior year.
• Long-Term Deferred Tax slipped to $84.2 million in Q1 2026 per IRWD's latest filing, from $103.4 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $335.4 million in Q1 2022 and troughed at $84.2 million in Q1 2026.
• A 5-year average of $206.9 million and a median of $206.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax declined 5.11% in 2022, then tumbled 45.13% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $283.7 million in 2022, then fell by 25.15% to $212.3 million in 2023, then tumbled by 32.07% to $144.2 million in 2024, then fell by 28.29% to $103.4 million in 2025, then retreated by 18.56% to $84.2 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $84.2 million, $103.4 million, and $101.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.